Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • believe220000 believe220000 Jul 1, 2013 2:32 PM Flag

    Results For Insmed's Arikace Disappoints; Shares Fall 19% 07/01 02:23 PM

    02:23 PM EDT, 07/01/2013 (MidnightTrader) -- Insmed (INSM:$9.68,00$-2.28,00-19.06%) shares down 19% at $9.66 as phase 3 study results for INSM's drug Arikace disappoint. Arikace, which treats certain lung infections in patients with cystic fibrosis, met the study's primary endpoint, but investors were hoping for the drug to show superiority over other treatments, specifically Novartis's (NVS) Tobi which showed more favorable results.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 02:23 PM EDT, 07/01/2013 (MidnightTrader) -- Insmed (INSM:$9.68,00$-2.28,00-19.06%) shares down 19% at $9.66 as phase 3 study results for INSM's drug Arikace disappoint. Arikace, which treats certain lung infections in patients with cystic fibrosis, met the study's primary endpoint, but investors were hoping for the drug to show superiority over other treatments, specifically Novartis's (NVS) Tobi which showed more favorable results.

    • 02:23 PM EDT, 07/01/2013 (MidnightTrader) -- Insmed (INSM:$9.68,00$-2.28,00-19.06%) shares down 19% at $9.66 as phase 3 study results for INSM's drug Arikace disappoint. Arikace, which treats certain lung infections in patients with cystic fibrosis, met the study's primary endpoint, but investors were hoping for the drug to show superiority over other treatments, specifically Novartis's (NVS) Tobi which showed more favorable results

 
INSM
24.03+0.15(+0.63%)Jul 2 4:00 PMEDT